What Institut Merieux does

Institut Mérieux is a family-owned bioindustrial holding company founded in 1897 in Lyon, France by Marcel Mérieux and now led by Chairman Alain Mérieux, Vice-Chairman Alexandre Mérieux, and CEO Michel Baguenault. It consolidates four core operating subsidiaries: bioMérieux, a global leader in in vitro diagnostics for clinical and industrial applications that generated €4,070 million in 2025 revenue across 45 countries; Mérieux NutriSciences, which provides food safety testing, auditing, and certification through 140 ISO 17025 accredited laboratories in 32 countries; Transgene, a clinical-stage biotechnology company in Strasbourg using its myvac® AI-augmented neoantigen platform to develop individualized cancer vaccines, with TG4050 in Phase 1/2 trials; and Mérieux Equity Partners, an AMF-licensed investment manager overseeing over €1.6 billion across roughly 35 European healthcare portfolio companies. The group also holds minority strategic stakes in Ceva Santé Animale (animal health, since 2025) and OXB/Oxford Biomedica (gene therapy, since 2023), and is partially capitalized by EXOR since 2022.

The group operates across the entire One Health value chain, from prevention and food safety to clinical diagnostics, immunotherapy, and healthcare investment, unified by a public health mission to combat infectious diseases. Its combined revenue of €4.9 billion is supported by 26,000+ employees across 50+ countries, with 93% of sales generated outside France and approximately 11% of revenue reinvested in R&D. The Mérieux family's founding Pasteurian heritage, long-dated capital, and integrated ecosystem (including Fondation Mérieux and Mérieux Université) differentiate the holding from purely financial or industrial peers and enable patient investment in adjacent areas such as advanced therapies and antimicrobial resistance.

Revenue mechanics are diversified by subsidiary and business model: bioMérieux sells instruments, reagents, and diagnostic services through direct enterprise sales; Mérieux NutriSciences operates a fee-for-service laboratory and certification model; Transgene generates licensing, partnership, and milestone revenue from therapeutic development; and Mérieux Equity Partners earns management and performance fees on its healthcare investment funds. End customers include hospital laboratories, pharma and cosmetics manufacturers, agri-food companies, oncology clinical trial sites, and European healthcare growth companies, with no individually material customer concentration disclosed at the holding level.

Name

Institut Merieux

Legal name

Institut Mérieux

Website

https://institut-merieux.com

Company type

Private

Founded year

1897

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Institut Mérieux is a family-owned bioindustrial holding company that consolidates bioMérieux (in vitro diagnostics), Mérieux NutriSciences (food safety testing), Transgene (cancer immunotherapy), and Mérieux Equity Partners (healthcare investment), serving hospitals, industrial customers, and European healthcare companies globally.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

Management of Companies and Enterprises (551), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Laboratory Analytical Instruments (3826), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Supply Chain & Procurement Organizations (HLAJAKAL)

akta.pro secondary industries

Global Supply Chain, Procurement & Market-Shaping Partnerships (Medicines/Diagnostics/Vaccines) (HLAJAOAK), Veterinary Vaccine & Biologics Distributors (HLAMAIAC), Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF), Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

• In vitro diagnostics
• Food safety testing
• Cancer immunotherapy
• Healthcare investment management
• Public health solutions

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. bioMérieux - In Vitro Diagnostics: Global leader in in vitro diagnostics for clinical and industrial applications. Revenue generated from diagnostic instruments, reagents, and testing services. 2025 revenue of €4,070 million.
2. Mérieux NutriSciences - Food Safety Testing: Laboratory testing, auditing, certification, consultancy, labeling support, digital solutions, and training for food quality and safety. Operates 140 ISO 17025 accredited laboratories in 32 countries.
3. Transgene - Biotech R&D: Clinical-stage biotechnology company developing immunotherapies for cancer. Revenue model based on licensing, partnerships, and potential milestone payments from therapeutic development.
4. Mérieux Equity Partners - Investment Management: AMF-licensed asset management company investing in European healthcare companies. Manages over €1.6 billion across ~35 active portfolio companies through venture and buyout strategies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Institut Mérieux is a family bioindustrial holding company that controls majority stakes in bioMérieux (in vitro diagnostics for clinical and industrial applications), Mérieux NutriSciences (food safety testing, auditing, certification, and consultancy), Transgene (clinical-stage cancer immunotherapies), and Mérieux Equity Partners (European healthcare investment management). The group sells diagnostic instruments, reagents, laboratory testing services, immunotherapy candidates, and investment fund products across 50+ countries.

Product overview

Institut Mérieux is a family bioindustrial holding company founded in 1897, majority shareholder in four core companies: bioMérieux (in vitro diagnostics for clinical and industrial applications), Mérieux NutriSciences (food safety testing and certification), Transgene (cancer immunotherapies via myvac® AI-powered platform), and Mérieux Equity Partners (healthcare investment management). The group operates across the entire health value chain from prevention and diagnosis to innovative therapies and health investment, united by a public health mission to combat infectious diseases globally.

Differentiator

Problem solved

Functional benefit

Products and services

• bioMérieux Global leader in in vitro diagnostics serving public health for over 60 years. Offers clinical diagnostics for identifying infection-causing microorganisms and antimicrobial resistance, plus industrial safety and quality solutions for food, pharmaceutical, and cosmetic sectors. Generated €4,070 million in 2025 revenue with 15,000 employees worldwide.
• Mérieux NutriSciences
• Transgene
• Mérieux Equity Partners AMF-licensed investment management company investing in European healthcare companies at various maturity stages. Conducts venture/innovation capital and buyout activities. Manages over €1.6 billion across approximately 35 active portfolio companies.

Quantifiable outcome

• €4.9 billion combined group revenue
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor, major and core.

• emlyon business schoolminorStrategic or Co-development Partner · 8 April 2026Partnership for the 'One Health: Our Best Defense' conference held at IARC in Lyon on April 8, 2026, bringing together scientists, economists, public health leaders, and private sector representatives.
• IARC (International Agency for Research on Cancer)minorStrategic or Co-development Partner · 8 April 2026Host venue for the One Health conference. Dr. Elisabete Weiderpass, IARC Director, participated in the conference discussing cancer prevention within the One Health framework.
• Africa CDCminorStrategic or Co-development Partner · 1 January 2026Dr. Ngashi Ngongo of Africa CDC participated in the One Health conference. Africa CDC confirmed priorities on accelerating access to diagnostics, antibiotics, and vaccines including a continental procurement mechanism.
• PAHO (Pan American Health Organization)minorStrategic or Co-development Partner · 1 January 2026Dr. Jarbas Barbosa da Silva Jr, PAHO Executive Director, participated in the One Health conference discussing integrated surveillance and the organization's 42-year regional procurement mechanism.
• Ceva Santé AnimalemajorStrategic or Co-development Partner · 1 January 2025Institut Mérieux entered the capital of Ceva Santé Animale in 2025, forming a strategic partnership. Ceva is a major animal health company. This acquisition reflects the group's commitment to the One Health approach, uniting human and veterinary health under the same umbrella.
• OXB (Oxford Biomedica)coreStrategic or Co-development Partner · 1 January 2023Institut Mérieux entered the capital of OXB (Oxford Biomedica) in 2023. OXB is a gene therapy specialist. Alexandre Mérieux was appointed Chairman of OXB's Board, strengthening the strategic partnership.
• Lyonbiopôle Auvergne-Rhône-AlpescoreStrategic or Co-development Partner · 1 January 2005Via bioMérieux, Institut Mérieux is a founding member of Lyonbiopôle, a competitiveness cluster dedicated to health. Since 2005, the cluster has brought together industry players, SMEs, academics, and hospital stakeholders to support innovative healthcare solutions.

Scale indicators10 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• bioMérieux: Euronext Paris-listed subsidiary in which Institut Mérieux holds ~60%; the global in vitro diagnostics business that anchors group revenue. Listed alongside Institut Mérieux for valuation comparability within the IVD peer set (vs. Roche, Abbott, BD, Qiagen).
• SGS SA: Swiss global testing, inspection, and certification (TIC) leader with food, life-sciences, and agri-food testing labs. Closest peer to Mérieux NutriSciences at scale, providing comparable revenue mix and accreditation-driven economics.
• Qiagen: Germany-based molecular diagnostics and sample-preparation specialist. Comparable to bioMérieux's molecular and infectious-disease franchises and a key competitor in hospital laboratory PCR/testing workflows.
• Hologic: US diagnostics company focused on women's health, molecular diagnostics, and infectious disease. Comparable mid-cap diagnostics peer for bioMérieux in molecular and rapid-test menu economics and capital allocation benchmarks.
• Eurofins Scientific: Luxembourg/France-based testing-services platform with bioanalytical, food, pharmaceutical and clinical-diagnostics laboratories across 60+ countries. Closest peer to Mérieux NutriSciences for food/pharma testing and a relevant comparator for the group's lab-network economics.
• Bureau Veritas: Paris-listed testing, inspection, and certification (TIC) major operating agri-food and commodity laboratories globally. Closely comparable to Mérieux NutriSciences and a same-region (France) listed peer for valuation reference.
• Roche Holding: Swiss family-controlled healthcare group with a Diagnostics Division (the largest pure-play IVD franchise globally) and a pharmaceuticals arm. Closest analog to Institut Mérieux's combination of dominant IVD market share with a long-duration ownership structure and integrated healthcare mission.

Broad incumbents

• Thermo Fisher Scientific: US life-sciences tools and diagnostics platform spanning analytical instruments, reagents, and clinical diagnostics. Comparable as a broad incumbent whose instrument + consumables model parallels bioMérieux's revenue mechanics.
• Boehringer Ingelheim: German family-owned pharma group that absorbed Mérial (animal health) following Institut Mérieux's 1994 vaccine divestiture. Comparable as a family-controlled bioindustrial player with significant human-pharma + animal-health exposure relevant to Ceva.
• Danaher Corporation: US diversified life-sciences platform owning Beckman Coulter, Cepheid, Leica Biosystems, and IDT — directly comparable to bioMérieux in clinical diagnostics. A broad incumbent with a roll-up acquisition model rather than family-holding structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/institut-merieux

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Merieux